tbuckley/cabot-search huggingface dataset:
Oxaliplatin reintroduction for colorectal cancer patients who were refractory or intolerant to oxaliplatin
Authors: Toshihiko Matsumoto, Takashi Oda, Shintaro Nanba, Takao Tuzuki, Takanori Watanabe, Shinjiro Takagi, Yasushi Hiramatsu, Masahiro Takatani, Hirofumi Morishita, Hiroaki Okushin
Journal: Annals of Oncology (2017)
PS02.02 Oral Bisphosphonate Use and Lung Cancer Incidence among Postmenopausal Women
Authors: M. Tao, S. Chen, J.L. Freudenheim, J.A. Cauley, K.C. Johnson, X. Ma, G.E. Sarto, H. Wakelee, P. Boffetta, J. Wactawski-Wende
Journal: Journal of Thoracic Oncology (2017)
The Las Vegas Shootings—Underscoring Key Features of the Firearm Epidemic
Authors: James M. Shultz, Siri Thoresen, Sandro Galea
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MSF pushes down price of generic hepatitis C drugs to new low level
Authors: Jacqui Wise
Journal: BMJ (2017)

The medical humanitarian charity Medecins sans Frontieres (MSF) has secured deals on generic formulations of the hepatitis C treatments sofosbuvir and daclatasvir for as low as US $1.40 (£1.05; €1.20) a day or $120 for a 12 week course.1 This is a dramatic reduction on the original price tag of $147 000 for a 12 week course of the branded versions.

MSF is calling on governments worldwide to work harder to bring down prices of hepatitis C drugs to a similar low level to expand access to treatment.

The combination of sofosbuvir and daclatasvir has been shown to be highly effective in treating hepatitis C virus infection, with cure rates of up to 95% and fewer side effects than with previous treatments. But access to the direct acting antivirals has been limited in …
Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments
Authors: Panchanan Maiti, Jayeeta Manna, Gary L. Dunbar
Journal: Translational Neurodegeneration (2017)

Gradual degeneration and loss of dopaminergic neurons in the substantia nigra, pars compacta and subsequent reduction of dopamine levels in striatum are associated with motor deficits that characterize Parkinson's disease (PD). In addition, half of the PD patients also exhibit frontostriatal-mediated executive dysfunction, including deficits in attention, short-term working memory, speed of mental processing, and impulsivity. The most commonly used treatments for PD are only partially or transiently effective and are available or applicable to a minority of patients. Because, these therapies neither restore the lost or degenerated dopaminergic neurons, nor prevent or delay the disease progression, the need for more effective therapeutics is critical. In this review, we provide a comprehensive overview of the current understanding of the molecular signaling pathways involved in PD, particularly within the context of how genetic and environmental factors contribute to the initiation and progression of this disease. The involvement of molecular chaperones, autophagy-lysosomal pathways, and proteasome systems in PD are also highlighted. In addition, emerging therapies, including pharmacological manipulations, surgical procedures, stem cell transplantation, gene therapy, as well as complementary, supportive and rehabilitation therapies to prevent or delay the progression of this complex disease are reviewed.
Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors.
Authors: Wael A. Harb, Cristiana Sessa, Hal W. Hirte, Stanley B. Kaye, Susana N. Banerjee, Alexandra Christinat, Ronit Simantov, Margaret Singh, David W. Sternberg, Rebecca Light, Srinivasu Poondru, R. Wendel Naumann
Journal: Journal of Clinical Oncology (2013)

e13502 Background: Linsitinib (OSI-906) is an oral inhibitor of IGF-1R and IR. Increased IGF-1R and IR activity is observed in human cancers and implicated in resistance to chemotherapy. In preclinical studies, linsitinib blocked IGF-1R/IR-AKT pathway activity evoked by PAC treatment. This study combines linsitinib + a cytotoxic agent. Methods: Pts with advanced solid tumors received weekly IV PAC (80mg/m2) in 21-day cycles with intermittent linsitinib (Arm A, d1-3q7d) or continuous linsitinib (Arm B, B2 and B3, twice daily (BID) d1-21). The primary objective was to determine the maximum tolerated dose (MTD) of linsitinib + PAC using a standard 3+3 phase I design. Results: 58 pts were treated (49F:9M, median age 58 yrs). Linsitinib doses of 300mg to 600mg daily (QD) d1-3q7d in Arm A and 75mg to 150 mg BID in Arm B were evaluated. Dose limiting toxicities in Arm A (n=27) were grade G3 neutropenia, G2 neuropathy and G3 deep vein thrombosis (DVT), and in Arm B (n=31) were G3 hyperglycemia, G3 fatigue (n=2) and G4 pulmonary embolism (PE). DVT and PE were reported as unrelated to linsitinib. MTD: Arm A = 600mg QD d1-3q7d Arm B = 150mg BID. Most common drug-related toxicities in ≥20%were (any grade; G3): fatigue (60%; 15.5%), nausea (48%; 0%), alopecia (48%; 0%), diarrhea (36%; 5%), drug eruption (21%; 2%), neuropathy (26%; 2%) and dysgeusia (24%; 0%). The median duration of exposure (days) for Arm A was 64.5, 91.0, 132.0 and 159.5 for the 300mg, 400mg, 450mg and 600mg doses, respectively. In Arm B, median duration of exposure (days) was 232.0 and 87.5 for the 75mg and 150mg doses, respectively. Partial response was achieved in 6 pts (10%)-3 ovarian, 1 primary peritoneal, 1 endometrial, and 1 esophageal. Stable disease was achieved in 25 pts (43%) - 10 ovarian, 2 primary peritoneal, 1 endometrial, and 12 pts in other tumor types. Pharmacokinetic (PK) results suggested no substantial PK interaction when linsitinib was administered 2 hours prior to PAC. Conclusions: Linsitinib + PAC did not show any unexpected safety concerns given the known mechanism of action, at doses up to the single agent MTDs. Clinical trial information: NCT00889382.
TCT-555 Post-Balloon Dilation Following TAVR Implantation Increases Pacemaker Dependency
Authors: Rachel Kaplan, Ajay Yadlapati, Rod Passman, Bradley Knight, Ranya Sweis, Mark Ricciardi, Duc Thinh Pham, S. Malaisrie, Charles Davidson, James Flaherty
Journal: Journal of the American College of Cardiology (2017)
TCT-644 Clinical Outcomes of Acute Coronary Syndrome (ACS) Patients With Deferred PCI Based on Non-ischemic Fractional Flow Reserve (FFR) Values
Authors: Hussain Ibrahim, Muhammad Choudhry, Wasiq Zaidi, Yussr Ibrahim, Saad Sikanderkhel, Adnan Khan, Mohamed Almahmoud, Wissam Khalife, Umamahesh Rangasetty, Syed Gilani
Journal: Journal of the American College of Cardiology (2017)
Prevention of multidrug-resistant infections from contaminated duodenoscopes: Position Statement of the European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology Nurses and Associates (ESGENA)
Authors: Ulrike Beilenhoff, Holger Biering, Reinhard Blum, Jadranka Brljak, Monica Cimbro, Jean-Marc Dumonceau, Cesare Hassan, Michael Jung, Christiane Neumann, Michael Pietsch, Lionel Pineau, Thierry Ponchon, Stanislav Rejchrt, Jean-François Rey, Verona Schmidt, Jayne Tillett, Jeanin van Hooft
Journal: Endoscopy (2017)

Patients should be informed about the benefits and risks of endoscopic retrograde cholangiopancreatography (ERCP)Only specially trained and competent personnel should carry out endoscope reprocessing.Manufacturers of duodenoscopes should provide detailed instructions on how to use and reprocess their equipment.In the case of modifications to their equipment, manufacturers should provide updated instructions for use.Detailed reprocessing protocols based on the manufacturer's instructions for use should clearly lay out the different reprocessing steps necessary for each endoscope model.Appropriate cleaning equipment should be used for duodenoscopes in compliance with the manufacturer's instructions for use. Only purpose-designed, endoscope type-specific, single-use cleaning brushes should be used, to ensure optimal cleaning. As soon as the endoscope is withdrawn from the patient, bedside cleaning should be performed, followed by leak testing, thorough manual cleaning steps, and automated reprocessing, in order to: · Remove debris from external and internal surfaces;. · Prevent any drying of body fluids, blood, or debris;. · Prevent any formation of biofilms.. In addition to the leak test, visual inspection of the distal end as well as regular maintenance of duodenoscopes should be performed according to the manufacturer's instructions for use, in order to detect any damage at an early stage.The entire reprocessing procedure in endoscope washer-disinfectors (EWDs) should be validated according to the European and International Standard, EN ISO 15883. Routine technical tests of EWDs should be performed according to the validation reports.Microbiological surveillance of a proportion of the department's endoscopes should be performed every 3 months, with the requirement that all endoscopes used in the unit are tested at least once a year.In the case of suspected endoscopy-related infection, the relevant device (e. g., endoscope, EWD) should be taken out of service until adequate corrective actions have been taken. Outbreaks should be managed by a multidisciplinary team, including endoscopy, hygiene, and microbiology experts, manufacturers, and regulatory bodies, according to national standards and/or laws. In the case of suspected multidrug-resistant organism (MDRO) outbreaks, close cooperation between the endoscopy unit and the clinical health provider is essential (including infection control departments and hospital hygienists).
Seis años de vigilancia de la hepatitis A y B en la medicina general en Francia
Authors: A Flahault, P Maison, N Farran, V Massari
Journal: Eurosurveillance (1997)

La red centinela francesa esta compuesta por medicos generales que registran de forma continua casos de siete patologias infecciosas (sindromes gripales, diarrea aguda, varicela, parotiditis, sarampion, uretritis masculina y hepatitis aguda de probable etiologia viral) y analisis de VIH. Este sistema de vigilancia permite vigilar continuamente la incidencia de infecciones por hepatitis A y B (VHA y VHB) en la Francia metropolitana.
Carta à redacção : Surtos de parvovirus B19
Authors: H Kelly, J Leydon
Journal: Eurosurveillance (2005)

In a recent issue of Eurosurveillance, Goncalves and colleagues reported that outbreaks of a rash illness in a kindergarten, a primary and a secondary school in the local health area of Braga in northern Portugal were due to human parvovirus B19 [1]. Alth
Contrôles de qualité pour le diagnostic des maladies virales en vue d’améliorer la réponse aux alertes en Europe
Authors: O Donoso-Mantke, H Schmitz, H Zeller, P Heyman, A Papa, M Niedrig
Journal: Eurosurveillance (2005)

La menace que representent les maladies infectieuses emergentes et re-emergentes, et depuis plus recemment, la dissemination deliberee d’agents infectieux dans une population sensible, est consideree tres serieusement tant au niveaux national qu’international. En sante publique, les efforts pour renforcer la detection, la surveillance et le controle de ces maladies ont redouble. Cependant, les cliniciens et les laboratoires cliniques jouent un role important dans la detection precoce des maladies, l’identification de l’agent presume, et la notification aux autorites competentes. Pour etre efficaces dans ce role, les laboratoires doivent etre specialement prepares a manipuler les agents viraux en toute securite et ont besoin, entre autres, de tests de diagnostic adequats sensibles et rapides. Le Reseau europeen de diagnostics des maladies virales « importees » (European Network for Diagnostics of “Imported” Viral Diseases, ENIVD), cree en 1998, compte actuellement parmi ses membres permanents 44 laboratoires d’expertise dans 21 Etats membres de l’Union Europeenne (UE) et quatre pays hors UE. ENIVD fait partie des reseaux sur les maladies transmissibles finances par la Commission Europeenne. Le reseau ENIVD s’acquitte de plusieurs tâches essentielles a la surveillance et au controle des infections virales importees, rares et emergentes, telles que l’echange d’expertises et l’organisation de programmes de controle de qualite externe necessaires pour ameliorer les diagnostics. L’article presente ici fait une synthese des donnees provenant des activites recentes de controle de qualite externe centrees sur les diagnostics des infections a hantavirus, virus de la fievre dengue, filovirus, virus de la fievre de Lassa, orthopox virus et coronavirus du SRAS. Ces analyses ont ete faites entre 1999 et 2004 et incluaient 93 laboratoires de 41 pays, y compris des laboratoires de pays supplementaires hors Europe. Dans un avenir proche, les pays candidats a l’UE, et les pays de l’est voisins seront invites a joindre le reseau. Un site internet est accessible au public a l’adresse http://www.enivd.de.
Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073–1081
Authors: Michaël J.B. van Baar, Daniël H. van Raalte, Marcel H.A. Muskiet
Journal: Diabetes Care (2017)

We read with interest the study by Lovshin et al. (1) investigating the natriuretic effect of the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin in patients with type 2 diabetes (T2D). The authors report that 1 month of sitagliptin therapy increases creatinine-based fractional sodium excretion (FENa) compared with placebo, which is in line with our previous observation (2). As lithium clearance and (intra)renal hemodynamics were not affected, the authors suggest that sitagliptin inhibits tubular sodium reabsorption at a level that is likely downstream of the macula densa. In parallel with enhanced FENa, DPP-4 inhibition increased intact stromal cell–derived factor (SDF)-1α1–67 levels, suggesting a relevant natriuretic role for this DPP-4 substrate. We agree with the authors that their mechanistic findings are of potential clinical relevance, particularly when hypothesizing about the added natriuretic effect of combined pharmacological DPP-4/sodium–glucose cotransporter …
Men develop atrial fibrillation 10 years earlier than women, finds study
Authors: Susan Mayor
Journal: BMJ (2017)

Men develop atrial fibrillation (AF) an average of 10 years earlier than women, and weight is a major risk factor, a pooled analysis of four large European community based studies has found.1

AF is the most common heart rhythm disorder, and its prevalence is increasing. Previous studies have shown that it is twice as common in men as in women, but the risk of adverse outcomes such as stroke is higher in women.

Researchers followed up 79 793 middle aged people (median age 49.6 years) in four community based European cohorts from Denmark, Finland, …
Evidence-Based Pragmatic Psychiatry—A Call to Action
Authors: Martin P. Paulus
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Efficacy of EGFR tyrosine kinase inhibitors for EGFR mutatnt non-small cell lung cancer with brain metastases
Authors: Yu Saida, Tetsuya Abe, Ko Sato, Kosuke Ichikawa, Ryo Ito, Masaaki Okajima, Satoru Miura, Satoshi Watanabe, Hiroshi Tanaka, Toshiaki Kikuchi
Journal: Annals of Oncology (2017)
TCT-750 First Generation Versus Second Generation Drug-eluting Stents for Restenosis with Stent Fracture after Drug-eluting Stents Implantation
Authors: Arata Sano, Kazushige Kadota, Kazuki Matsushita, Akimune Kuwayama, Masanobu Ohya, Takenobu Shimada, Hidewo Amano, Shunsuke Kubo, Seiji Habara, Hiroyuki Tanaka, Yasushi Fuku
Journal: Journal of the American College of Cardiology (2017)
La rosolia in Inghilterra, Scozia e Galles
Authors: P Tookey
Journal: Eurosurveillance (2004)

Nel Regno Unito i vaccini contro la rosolia per le bambine in eta scolare sono stati introdotti dal 1970, seguiti da altre misure nel corso degli anni '70: il test prenatale e la vaccinazione post-partum per le donne suscettibili. Nel 1988 e stata introdotta la vaccinazione di massa contro Morbillo Parotite e Rosolia (MPR) nei bambini di 12-15 mesi; la vaccinazione delle bambine in eta scolare e stata interrotta nel 1996 e rimpiazzata da una seconda dose di vaccino MPR per i bambini in eta prescolare. Per contro, la vaccinazione post-partum delle donne suscettibili identificate con il test prenatale e rimasta in programma. La rosolia e diventata una malattia a notifica obbligatoria nel 1988, e viene monitorata per mezzo di dati clinici e di laboratorio. Sono disponibili i dati sulle interruzioni volontarie di gravidanza legate alla rosolia, sulle nascite di bambini affetti da sindromi da rosolia congenita (RC), sulla suscettibilita alla rosolia in sotto-gruppi di popolazione e sulle vaccinazioni. Le notifiche di casi di rosolia sono diminuite da circa 50 per anno tra il 1971 e il 1975 a un po' piu di 20 per anno nel periodo 1986-90, e le interruzioni di gravidanza sono passate da una media di 750 per anno a 50. Dal 1991 sono stati registrati circa 40 neonati con RC, con un terzo delle loro madri che si erano infettate all'estero, nel loro paese d'origine per la maggior parte (infezioni importate), un terzo erano nate all'estero ma erano state infettate nel Regno Unito e un terzo erano nate nel Regno Unito. Le donne residenti nel Regno Unito ma nate all'estero sono molto piu suscettibili alla rosolia delle donne nate nel Regno Unito. Nonostante la circolazione del virus della rosolia sia attualmente molto ridotta, la somministrazione del vaccino MPR l'ha ridotta di oltre il 10% dal 1995. Se il virus ricominciasse a circolare, le donne immigrate avrebbero un rischio maggiore di essere infettate dalla rosolia durante la gravidanza.
TCT-287 Comparison of Multivessel Percutaneous Coronary Intervention with Coronary Artery Bypass Graft Surgery for Patients with Severe Coronary Artery Disease Presenting with Non-ST-segment Elevation Acute Coronary Syndromes
Authors: Piotr Desperak, Michal Hawranek, Pawel Gasior, Aneta Ciślak, Marek Gierlotka, Lukasz Pyka, Andrzej Lekston, Mariusz Gasior
Journal: Journal of the American College of Cardiology (2017)
Public health surveillance in the UK revolutionises our understanding of the invasive Salmonella Typhimurium epidemic in Africa
Authors: Philip M. Ashton, Siân V. Owen, Lukeki Kaindama, Will P. M. Rowe, Chris R. Lane, Lesley Larkin, Satheesh Nair, Claire Jenkins, Elizabeth M. de Pinna, Nicholas A. Feasey, Jay C. D. Hinton, Timothy J. Dallman
Journal: Genome Medicine (2017)

The ST313 sequence type of Salmonella Typhimurium causes invasive non-typhoidal salmonellosis and was thought to be confined to sub-Saharan Africa. Two distinct phylogenetic lineages of African ST313 have been identified. We analysed the whole genome sequences of S. Typhimurium isolates from UK patients that were generated following the introduction of routine whole-genome sequencing (WGS) of Salmonella enterica by Public Health England in 2014. We found that 2.7% (84/3147) of S. Typhimurium from patients in England and Wales were ST313 and were associated with gastrointestinal infection. Phylogenetic analysis revealed novel diversity of ST313 that distinguished UK-linked gastrointestinal isolates from African-associated extra-intestinal isolates. The majority of genome degradation of African ST313 lineage 2 was conserved in the UK-ST313, but the African lineages carried a characteristic prophage and antibiotic resistance gene repertoire. These findings suggest that a strong selection pressure exists for certain horizontally acquired genetic elements in the African setting. One UK-isolated lineage 2 strain that probably originated in Kenya carried a chromosomally located bla CTX-M-15, demonstrating the continual evolution of this sequence type in Africa in response to widespread antibiotic usage. The discovery of ST313 isolates responsible for gastroenteritis in the UK reveals new diversity in this important sequence type. This study highlights the power of routine WGS by public health agencies to make epidemiologically significant deductions that would be missed by conventional microbiological methods. We speculate that the niche specialisation of sub-Saharan African ST313 lineages is driven in part by the acquisition of accessory genome elements.
Minister blames doctors for adverse reactions to mesh implants
Authors: Zosia Kmietowicz
Journal: BMJ (2017)

A health minister has blamed doctors and their “arrogance towards women” for the large number of patients who have reported life changing adverse effects from mesh implant surgery.

Jackie Doyle-Price, England’s social care minister, caused disappointment among campaigners on 18 October when she rejected calls for an immediate ban on the use of surgical mesh implants and for a public inquiry into the extent of adverse effects after their use for stress incontinence, vaginal prolapse, and hernia repair.

She also caused confusion when she said that guidance from the National Institute for Health and Care Excellence would be issued “before the end of the …